Tal Kafri

Tal Kafri, MD, PhD, is a UNC Lineberger Comprehensive Cancer Center member and Associate Professor of Microbiology and Immunology within the Gene Therapy Center at UNC-Chapel Hill School of Medicine. Kafri Lab is focused on the development of HIV-1 vectors for gene therapy of genetic and acquired human diseases, including hemophilia, Krabbe disease, and prostate cancer.

Tal Kafri

Associate Professor
UNC-Chapel Hill

7117 Thurston Bowles Chapel Hill

Area of interest

My research is focused on the development of HIV-l vectors for gene therapy of genetic diseases such as hemophilia-A, as well as a means to characterize the mechanism involved in recurrent prostate cancer.

Our studies are based on small and large animal models, including hemophilic animals (murine and canine) and nude mice with prostate cancer xenografts. The prostate cancer studies are aimed at characterizing the role of the androgen receptor (AR) pathway in recurrent prostate cancer. The working hypothesis of this study is that recurrent prostate cancer, which develops following castration, requires activation of the ARpathway. To test this hypothesis, a dominant negative (DN) ARcDNA and anti-ARshRNA are delivered to prostate cancer cells by inducible lentiviral vectors. The effects of the DN-ARand shRNA on androgen-dependent gene expression, cell growth, and tumor development are determined in vitro and in vivo.

Link to Publications on Reach NC site

Filed under: